FDA clears QIAstat-Dx bloodstream infection panel
Aug. 11, 2026—The FDA has cleared Qiagen’s QIAstat-Dx BCID GPF Plus AMR panel, the first QIAstat-Dx panel for bloodstream infections to receive FDA clearance.
Webinars and Commercial Conversations — Register Now
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, November 18, 2026, 12:00 PM-1 PM ET
Join leading pathology experts, Savitri Krishnamurthy, MD, and Marilyn Bui, MD, PhD, for a webinar exploring potential challenges in HER2 IHC testing for breast cancer, emerging evidence supporting digital and computational pathology as assistive tools for pathologists in HER2 IHC assessment, and practical considerations for real-world implementation and adoption.
Webinar presenters Savitri Krishnamurthy, MD, Professor of Pathology, Department of Anatomical Pathology The University of Texas MD Anderson Cancer Center, Houston, Texas, and Marilyn Bui, MD, PhD, Surgical Pathologist and Cytopathologist Member and Professor, Departments of Pathology, Machine Learning, and Translational Pathology, Scientific Director, Analytic Microscopy Core Chair, Women in Oncology Executive Board Moffitt Cancer Center, Tampa, Florida
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speakers are being compensated for their presentations. The program is not CME accredited and may not be used for CME credit.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, December 9, 2026, 12 PM-1 PM ET
Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers
Webinar presenter Michelle Shiller, DO, MSPT, Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Industry News
Proscia gets new clearance for Concentriq AP-Dx
Aug. 10, 2026—Proscia received a new FDA 510(k) clearance for the Concentriq AP-Dx, a digital pathology platform for primary diagnosis.
Roche expands cyclospora testing portfolio in U.S.
Aug. 7, 2026—Roche, in collaboration with subsidiary Tib Molbiol, released two research PCR testing options for labs to address the public health impact of the Cyclospora cayetanensis parasite.
Epredia adds BlockTracker, SlideTracker to portfolio
Aug. 6, 2026—Epredia announced an agreement with Canada-based manufacturer Lab Improvements to bring automated archiving to U.S. pathology labs, adding Lab Improvements’ BlockTracker and SlideTracker to its product portfolio.
Roche gets FDA clearance for Cobas BV/CV assay
July 29, 2026–Roche received FDA 510(k) clearance for its Cobas BV/CV assay.
Beckman Coulter launches DxU 1800 automated urinalysis solution
July 29, 2026—Beckman Coulter Diagnostics has launched in the U.S. its DxU 1800 system, a fully automated urinalysis solution that combines the new DxU 1800c chemistry analyzer with a DxU Iris microscopy analyzer.
Waters launches Xevo TQ Absolute XR IVD mass spectrometer
July 28, 2026—Waters Corp. launched the Xevo TQ Absolute XR IVD mass spectrometer, expanding its MassTrak IVD system portfolio of LC-MS/MS systems.
Hardy Diagnostics showcases rapid lateral flow assays to combat AMR
July 28, 2026—Antimicrobial resistance (AMR) remains one of the most significant challenges facing health care today.
Werfen hosts education event on anticoagulation management
July 28, 2026—Werfen is hosting an education event on Wednesday, July 29, titled “Leading Change in Anticoagulation Management: Anti-Xa for Unfractionated Heparin Monitoring Across Lab, Pharmacy and Clinical Teams.”
ZeptoMetrix molecular quality controls on NATtrol swabs
July 28, 2026—Beyond our traditional liquid format, ZeptoMetrix introduces molecular quality controls on swabs.